公开(公告)号：US20220290151A1

公开(公告)日：2022-09-15

申请号：US17635894

申请日：2020-09-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER

发明人： Andre PELEGRIN ,  Thierry CHARDES ,  Isabelle NAVARRO-TEULON ,  Maeva CHAUVIN

IPC分类号： C12N15/113 ,  C12N15/115 ,  A61P35/00

摘要： In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that MIS siRNA inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.

公开(公告)号：US20230040928A1

公开(公告)日：2023-02-09

申请号：US17783182

申请日：2020-12-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER

发明人： Andre PELEGRIN ,  Pierre MARTINEAU ,  Thierry CHARDES ,  Romain LANOTTE

IPC分类号： C07K16/32 ,  A61K47/68 ,  A61P35/00 ,  A61P15/00

摘要： The present invention relates to antibodies having specificity to HER4 and uses thereof, which are able to induce biased 4ICD routing/signaling. The inventors have isolated by antibody phage display three fully human anti-HER4 single-chain variable antibody fragment (scFv), selected on human HER4 extracellular domain, referred as C6 mAb, D5 mAb and F4 mAb and one fully human anti-HER4 scFv named H2 mAb, selected on NRG 1β1-stimulated EGFR/HER4 JMaCYT1-transfected NIH3T3 cells. In particular, the present invention relates to an isolated anti-HER4 antibody, wherein said antibody binds to an epitope of the HER4 protein.

公开(公告)号：US20180127510A1

公开(公告)日：2018-05-10

申请号：US15574515

申请日：2016-05-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER

发明人： Emmanuelle LIAUDET-COOPMAN ,  Thierry CHARDES ,  Pierre MARTINEAU ,  Yahya ASHRAF

IPC分类号： C07K16/30 ,  C07K16/40 ,  A61P35/00

CPC分类号： C07K16/3015 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76

摘要： The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.